Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multicenter, Randomized, Double Blind, Active-controlled, Parallel-group Phase III Study of Narlaprevir/Ritonavir and Pegylated Interferon/Ribavirin in 2 Patient Populations - naïve and Treatment Failure Patients With Genotype 1 Chronic Hepatitis C

NCT03833362 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT03833362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03833362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multicenter, Randomized, Double Blind, Active-controlled, Parallel-group Phase III Study of Narlaprevir/Ritonavir and Pegylated Interferon/Ribavirin in 2 Patient Populations - naïve and Treatment Failure Patients With Genotype 1 Chronic Hepatitis C
Lead sponsor
R-Pharm
Phase
Phase 3
Overall status
Completed
Start date
May 7, 2014
Completion date
February 21, 2017
Enrollment
420 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c